FreeCurrencyRates.com

इंडियन आवाज़     27 Nov 2022 07:12:04      انڈین آواز

Zenas BioPharma raises $118M for immunotherapy

AMN / WEB DESK

Zenas BioPharma has raised a $118 million series B to zoom in on a pipeline of immune-based therapies and launch a phase 3 for its lead candidate that was licensed from Xencor less than a year ago.

In addition to Enavate Sciences, which led the Series B equity financing, new Zenas shareholders include Longitude Capital, Vivo Capital, Rock Springs Capital, Perceptive Advisors, Agent Capital, Pivotal bioVenture Partners and Superstring Capital. Existing investors Fairmount, Wellington Management, Tellus BioVentures, Quan Venture Fund, and Xencor, Inc. also participated in the financing, which included the infusion of new capital as well as the conversion of convertible notes issued to certain of the investors in advance of the closing of the Series B financing.

Proceeds from the financing will support the clinical advancement of the company’s lead product candidate Obexelimab, including a global Phase 3 registration trial in patients with IgG4-related disease (IgG4-RD), which will be initiated in late 2022. In addition, the new funding will progress the company’s other global autoimmune disease programs into clinical development in 2023.

“We are thrilled to support Zenas as an innovative leader in biotechnology as the team executes the clinical development plans for IgG4-RD and the robust pipeline of immune-based therapies so adeptly acquired through strategic business development. We believe Zenas will successfully commercialize innovative therapies to improve the lives of those facing autoimmune and rare diseases,” said James Boylan, Chief Executive Officer of Enavate Sciences.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients around the world. With clinical development and operations globally, Zenas is advancing a deep and balanced global portfolio of potential first- and best-in-class autoimmune therapeutics in areas of high unmet medical need while meeting the value requirements of the dynamic global healthcare environment.

Leave a Reply

Your email address will not be published.

خبرنامہ

شعبۂ اردو، جامعہ ملیہ اسلامیہ کے پچاس سال مکمل

شعبے کے زیر اہتمام افتتاحی تقریب ، مذاکرہ ، مشاعرہ اور نمائش ...

بزنس ڈائری

ہندوستانی روپے میں بین الاقوامی تجارتی لین دین حکومت ہند ن ...

خوراک کے ضیاع کو روکنے کے لیے آپ کیا کریں؟

جاوید اختر اقو ام متحدہ کے خوراک اور زراعت سے متعلق ادارے (ا ...

MARQUEE

‘SARANG – Festival of India in Republic of Korea’ enthralls art, music lovers in South Korea

AMN / WEB DESK Indian Embassy in Seoul, South Korea organized annual flagship cultural program ‘SARANG ...

1.62 crore tourists visited J&K since Jan 2022, highest in 75 years

AMN Kashmir tourism era seems to be returning as after three decades, Kashmir Valley is attracting lakhs of ...

Varanasi nominated as first-ever SCO Tourism and Cultural Capital

Our Correspondent Varanasi has been nominated as the first-ever Shanghai Cooperation Organization (SCO) Tou ...

MEDIA

US: Ex-Congwoman of Indian origin Tulsi Gabbard joins Fox News

AMN / WEB DESK Former Hawaii congresswoman of Indian origin Tulsi Gabbard has joined Fox News as a paid con ...

DIGIPUB India condemns Delhi police action on The Wire editors

The Wire, its founder Siddharth Varadarajan, its founder editors Sidharth Bhatia and MK Venu and its deputy ed ...

SCIENCE / TECHNOLOGY

Telangana to have first Integrated Rocket Facility of country by Skyroot Aerospace

WEB DESK Telangana will have the first Integrated Rocket Design, Manufacturing, and Testing Facility of the ...

ISRO launches PSLV-C54 rocket carrying earth observation satellite Oceansat & 8 nano satellites

AMN / WEB DESK India's PSLV C 54 was launched from Sathish Dhawan Space Centre Sriharikota at 11.56 am toda ...

@Powered By: Logicsart